Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CCT301 38

Next Previous
X
Search
Drug Profile

CCT301 38

Alternative Names: CCT3-AXL-0038; CCT301-38

Latest Information Update: 17 Oct 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioAtla
  • Developer EXUMA Biotech; Fudan University Zhongshan Hospital; Shanghai PerHum Therapeutics; Shanghai Sinobioway Sunterra Biotechnology
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Renal cell carcinoma
  • Phase I Sarcoma

Most Recent Events

  • 17 Oct 2022 Preclinical trials in Sarcoma in USA (unspecified route) before October 2022 (Exuma Biotech pipeline, October 2022)
  • 20 Nov 2021 Phase-I clinical trials in Sarcoma in China (Late-stage disease, Metastatic disease, Second-line therapy or greater) (IV) (NCT05128786)
  • 12 Mar 2020 F1 Oncology is now called EXUMA Biotech

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top